Creative Planning’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.69M Buy
27,735
+3,088
+13% +$533K ﹤0.01% 1253
2025
Q4
$4.5M Buy
24,647
+3,369
+16% +$470K ﹤0.01% 1080
2025
Q3
$2.58M Buy
21,278
+5,198
+32% +$586K ﹤0.01% 1340
2025
Q2
$1.68M Sell
16,080
-1,336
-8% -$141K ﹤0.01% 1457
2025
Q1
$2.03M Buy
17,416
+5,149
+42% +$587K ﹤0.01% 1161
2024
Q4
$1.04M Buy
12,267
+1,413
+13% +$130K ﹤0.01% 1617
2024
Q3
$975K Buy
10,854
+2,489
+30% +$217K ﹤0.01% 1531
2024
Q2
$673K Buy
8,365
+1,149
+16% +$85.1K ﹤0.01% 1709
2024
Q1
$576K Buy
7,216
+364
+5% +$30.6K ﹤0.01% 1751
2023
Q4
$545K Buy
6,852
+464
+7% +$31K ﹤0.01% 1657
2023
Q3
$446K Buy
6,388
+13
+0.2% +$972 ﹤0.01% 1635
2023
Q2
$458K Sell
6,375
-371
-5% -$27.4K ﹤0.01% 1611
2023
Q1
$416K Sell
6,746
-2,469
-27% -$162K ﹤0.01% 1587
2022
Q4
$711K Sell
9,215
-6
-0.1% -$359 ﹤0.01% 1218
2022
Q3
$411K Buy
+9,221
New +$461K ﹤0.01% 1448
2021
Q3
Sell
-9,668
Closed -$652K 2123
2021
Q2
$652K Sell
9,668
-1,053
-10% -$63.2K ﹤0.01% 1129
2021
Q1
$607K Sell
10,721
-400
-4% -$28.1K ﹤0.01% 1300
2020
Q4
$906K Sell
11,121
-754
-6% -$56.4K ﹤0.01% 999
2020
Q3
$846K Sell
11,875
-6,175
-34% -$481K ﹤0.01% 874
2020
Q2
$1.49M Buy
18,050
+7,624
+73% +$587K ﹤0.01% 602
2020
Q1
$613K Sell
10,426
-3,886
-27% -$317K ﹤0.01% 847
2019
Q4
$1.48M Buy
+14,312
New +$578K ﹤0.01% 629

Other funds holding AXSM

Creative Planning's AXSM Position: Q1 2026 in Review

Creative Planning increased its Axsome Therapeutics (AXSM) stake by 13% in Q1 2026, buying an estimated $533K and bringing the position to 27,735 shares worth $4.69M. The position accounts for ﹤0.01% of the portfolio, ranked #1253.

Creative Planning first reported a position in AXSM in Q4 2019 and has held it in 22 quarters since. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Creative Planning held 27,735 shares of Axsome Therapeutics worth $4.69M as of Q1 2026.
  • Creative Planning bought 3,088 Axsome Therapeutics shares in Q1 2026, an estimated $533K.
  • Axsome Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #1253 holding.
  • Creative Planning first reported a position in Axsome Therapeutics in Q4 2019 and has held it in 22 quarters since.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.